Fragile X syndrome.
Journal
Current biology : CB
ISSN: 1879-0445
Titre abrégé: Curr Biol
Pays: England
ID NLM: 9107782
Informations de publication
Date de publication:
22 03 2021
22 03 2021
Historique:
entrez:
23
3
2021
pubmed:
24
3
2021
medline:
27
1
2022
Statut:
ppublish
Résumé
Paul Hagerman and Randi Hagerman introduce the X-linked neurodevelopmental disorder Fragile X syndrome (FXS) and discuss what causes this disorder and how it can be treated.
Identifiants
pubmed: 33756134
pii: S0960-9822(21)00076-2
doi: 10.1016/j.cub.2021.01.043
pii:
doi:
Substances chimiques
FMR1 protein, human
0
Fragile X Mental Retardation Protein
139135-51-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
R273-R275Subventions
Organisme : NICHD NIH HHS
ID : R01 HD036071
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests P.J.H. is a member of the Scientific Advisory Board of NeuCyte Pharmaceuticals, Inc. R.H. is a member of the Scientific and Clinical advisory committee of the National Fragile X Foundation (NFXF). R.H. is also on the Clinical Treatments Committee of the NFXF. R.H. is on the Tetra Advisory Committee and the Zynerba Scientific Advisory Committee.